OPHELIA
OFFICIAL TITLE: EFFECTIVENESS OF OLAPARIB PLUS TRASTUZUMAB IN HER2-POSITIVE BRCA-MUTATED OR HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) ADVANCED BREAST CANCER PATIENTS.
PROJECT DETAILS
THE OPHELIA STUDY IS A MULTICENTER, OPEN-LABEL, SINGLE-ARM, TWO COHORTS, SIMON’S TWO-STAGE MINIMAX DESIGN, PHASE II CLINICAL TRIAL.
THE PRIMARY OBJECTIVE OF THIS TRIAL IS TO ASSESS THE EFFICACY – AS DETERMINED BY THE OVERALL RESPONSE RATE (ORR) AND PROGRESSION-FREE SURVIVAL (PFS) BASED ON RECIST V.1.1 – OF OLAPARIB IN COMBINATION WITH TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE, GERMINAL BRCA1/2 MUTATED ABC.
TUMOR TYPE
PHASE
N
SITES
COUNTRY
STATUS
Recruiting
ESMO 2019 – DOWNLOAD THE POSTER
ESMO 2019 – DOWNLOAD LIST OF COI'S
OPHELIA SITES
